OmniAb Investor Conference Presentation Deck

Approved and Clinical-Stage Partner Pipeline NOW WITH THREE APPROVED PRODUCTS AND 22 ACTIVE CLINICAL-STAGE ANTIBODIES Program gloria ARCUS Zimberelimab BIOSCIENCES Partner Janssen gehason Jame Genentech* A Member of the Rache Group 基石药业 CSTONE PHARMACEUTICALS HANALLHARBOUR IMMUNOVANT BIONED Genmab MERCK Aptevo Janssen (chmen-dem Janssen toh Janssen b Genmab symphogen Servier Company symphogen a Servier Company symphogen a Servier Company symphogen a Servier Company abbvie + AstraZeneca AMGEN + SalubrisBio CURON Zhilkang Hongyi Boehringer Ingelheim Undisclosed Merck Confidential Sugemalimab Teclistamab Tiragolumab Batoclimab GEN1046 M6223 APVO436 JNJ-67371244 JNJ-70218902 JNJ-78306358 GEN1047 S095017 S095018 S095024 S095029 TNB-383B TNB-486 AMG 340 SAL003 CN1 Undisclosed Undisclosed Undisclosed M9140 Source Animal OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniMouse OmniMouse OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniFlic OmniFlic OmniFlic OmniRat OmniRat OmniRat OmniChicken OmniRat OmniRat Therapy Area Oncology Oncology Oncology Oncology Immunology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Metabolic Oncology Oncology Undisclosed Gastrointestinal Oncology Target PD-1 PD-L1 BCMA x CD3 TIGIT FcRn PD-L1 x 4-1BB TIGIT CD123 x CD3 CD33 x CD3 Undisclosed HLA-G x CD3 B7H4 x CD3 LAG-3 TIM-3 CD73 NKG2A BCMA x CD3 CD19 x CD3 PSMA x CD3 PCSK9 Undisclosed Undisclosed Undisclosed Undisclosed CEACAM-5 Preclinical Phase 1 Phase 2 Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020 Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved in China. Phase 3 * Indicates programs with fully paid licenses. + Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics. Registration Approved 39 OmniAb

View entire presentation